title: Keystone Symposium on Antibodies as Drugs: March 27-April 1, 2009, Whistler, BC CA.
abstract: The symposium on Antibodies as Drugs, organized by Keystone Symposia and chaired by J. Marks, (University of California Los Angeles, USA), E.S. Ward (University of Texas Southwestern Medical Center, USA) and L. Weiner (Georgetown University Medical Center, USA), was held in Whistler, British Columbia. This Canadian Rockies village, which will host the 2010 Olympic Games, served as an enchanting backdrop to the meeting. The more than 350 speakers and attendees included scientists from major pharmaceutical firms, e.g., Abbott, MedImmune/Astra Zeneca, Bristol-Myers Squibb, Merck & Co., Pfizer, Sanofi-Aventis, Schering, GlaxoSmithKline, Eli Lilly, Hoffmann LaRoche, Novartis, Wyeth, and biotechnology companies, e.g., Ablynx, Medarex, Morphosys, GenMab, Amgen, Genentech, ImmunoGen, Agensys, Domantis, Biogen Idec, Centocor, LFB, Micromet, PDL Biopharma, Borean Pharma, Dyax Corp., Symphogen and Syntonix. Academic research groups at Imperial College London, University of Oxford, ETH Zürich, Scripps, Institute Cochin, Karolinska Institute, Utrecht University, Harvard Medical School, Massachusetts Institute of Technology, Baylor College, Paul Ehrlich Institute, University of California San Francisco, University of California San Diego, University of Nantes, University of Tours and Ludwig Institute were also represented, as were regulatory authorities, including the US Food and Drug Administration, National Institutes of Health and the Public Health Agency of Canada). The meeting was very interactive and included thoughtful exchanges during the different sessions and networking events.
authors.affiliation: Centre d'Immunologie Pierre FABRE, Saint Julien en Genevois 74164, France. thierry.wurch@pierre-fabre.com
authors.forename: Thierry
authors.initials: T
authors.lastname: Wurch
authors.forename: Christel
authors.initials: C
authors.lastname: Larbouret
authors.forename: Bruno
authors.initials: B
authors.lastname: Robert
mesh_terms: D018033:Antibodies, Bispecific / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D002170:Canada; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy*; D016159:Tumor Suppressor Protein p53 / Q000187:drug effects* / Q000235:genetics
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D016159:Tumor Suppressor Protein p53